
Supporting the next generation in biotech
Gusztav Milotay started off his research career with Harwell Campus resident startup Etcembly as an intern in their microfluidics department after finishing his degree. Now, the company is supporting him with a bursary for his PhD at The University of Oxford. Gusztav shares what he learned during his time with Etcembly, and why he feels it’s so important for startups to give opportunities to fresh scientific talent.
My undergraduate degree in biochemistry took place right in the middle of the COVID-19 pandemic, which limited my real-world and lab experience. So at the end of my three-year course, I decided to step out of academia and try some hands-on work in the biotech field.
I had a strong interest in the immunotherapy space, particularly TCRs and antibodies, and the role of protein structure in target recognition. After speaking with Michelle Teng, the CEO, I was fascinated to hear about the work Etcembly was doing in discovering and optimising TCR-based therapeutics and how they were tackling this problem with generative AI.
Recognising the limited amount of data in the public domain available for training their own models, they decided to make some of their own. Jake Hurst, the company’s Chief Technology Officer, then explained the microfluidics sequencing platform they were developing to generate proprietary TCR sequence data for their machine learning models.
I had always thought that biotech was quite an unforgiving industry for people with limited expertise like myself. It makes sense – it’s a specialised field and small companies don’t have a lot of time or resources for training. So I was delighted when they offered me the opportunity to come and work with them on a paid internship.
During my time I managed to learn a huge amount, ranging from various aspects of labwork to computational biology to protein engineering to cloning. The members of the team really took the time to explain what they were doing and help me develop new skills, and I was blown away by how friendly and patient everyone was. In turn, I noticed that having to communicate with other students helped to solidify my understanding – it’s only when you truly understand something that you can explain it in a way that people can grasp.
I think I also brought a fresh perspective by being a newbie in the field, asking the questions that made people see the bigger picture to solve the challenges they were facing. While I was there, the team successfully developed their first picomolar affinity bispecific TCR-based immune engager, which was amazing to see.
Although I was really enjoying being part of the Etcembly team, I realised that I did want to pursue a PhD. My initial plan was to go back to London, but then the team at Etcembly floated the idea of working in Oxford in Ben Fairfax’s lab. He’s a medical oncologist looking at interpatient variation in response to checkpoint inhibitors and the applications of immunotherapy in treating cancer. He has an extensive patient cohort and is doing a lot of single-cell work, so the opportunity seemed perfect for me.
The Etcembly team really got on board and made it happen – and not only helped me secure this position but also supported me with a bursary. They’ve given me freedom in both my experience at Etcembly and what I will pursue during my PhD.
I’m so grateful to Etcembly for giving me a chance to get stuck into the lab, and for their continuing support as I develop as a scientist. I owe a lot to them, and I hope I’ve been a worthwhile investment as I continue to progress my research career.
Related news
-
Amber Therapeutics Takes Space at Harwell Campus
Amber Therapeutics, an innovative medical technology company developing a breakthrough implantable therapy to treat women with urinary incontinence, has taken over 7,000 sq. ft of space in Harwell’s new Tech Foundry development to build a new HQ for its R&D, manufacturing and production capabilities. The company was founded in 2021 with core backing from Oxford…
-
ISIS Launches book to celebrate 40 Years of Scientific Triumph from Net Zero to Cancer Research
To celebrate 40 years of the ISIS Neutron and Muon source, the research facility has launched a coffee table book that showcases all aspects, and key milestones, of operations over last four decades: from science to staff and instruments to infrastructure. Established in 1984 and inaugurated in 1985 by then Prime Minister Margaret Thatcher, ISIS has since become a…
-
Harwell Innovation Centre Celebrates 25 Years of Supporting Science and Startups
Harwell Innovation Centre is celebrating 25 years at the heart of the UK’s innovation landscape. Since opening its doors in 2000, the centre has supported pioneering startups and scale-ups in sectors ranging from space and energy to life sciences and quantum tech. Located on Harwell Campus, Harwell Innovation Centre, which is managed by Oxford Innovation…